



April 7, 2020

Natalie A. Gustafson, PharmD, Director/Co-Owner
Lloyd Central Compounding Pharmacy
2606 NE Broadway Street, Suite B
Portland, OR 97232

Dear Dr. Gustafson:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Portland Compounding Pharmacy, LLC dba Lloyd Central Compounding Pharmacy, located at 2606 NE Broadway Street, Suite B, Portland, Oregon 97232, from November 13, 2019, to November 26, 2019, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Oregon State Board of Pharmacy for follow up.

When the agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact William Millar, Compliance Officer, at (503) 671-9711 Ext. 30, or by email at William.Millar@fda.hhs.gov.

Sincerely,

A handwritten signature in black ink, appearing to read "Steven Porter".

CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

SP:wm